169 related articles for article (PubMed ID: 36530982)
1. BPTF promotes the progression of distinct subtypes of breast cancer and is a therapeutic target.
Bezrookove V; Khan IA; Nosrati M; Miller JR; McAllister S; Dar AA; Kashani-Sabet M
Front Oncol; 2022; 12():1011173. PubMed ID: 36530982
[TBL] [Abstract][Full Text] [Related]
2. The role of BPTF in melanoma progression and in response to BRAF-targeted therapy.
Dar AA; Nosrati M; Bezrookove V; de Semir D; Majid S; Thummala S; Sun V; Tong S; Leong SP; Minor D; Billings PR; Soroceanu L; Debs R; Miller JR; Sagebiel RW; Kashani-Sabet M
J Natl Cancer Inst; 2015 Feb; 107(5):. PubMed ID: 25713167
[TBL] [Abstract][Full Text] [Related]
3. Autophagy-Dependent Sensitization of Triple-Negative Breast Cancer Models to Topoisomerase II Poisons by Inhibition of the Nucleosome Remodeling Factor.
Tyutyunyk-Massey L; Sun Y; Dao N; Ngo H; Dammalapati M; Vaidyanathan A; Singh M; Haqqani S; Haueis J; Finnegan R; Deng X; Kirberger SE; Bos PD; Bandyopadhyay D; Pomerantz WCK; Pommier Y; Gewirtz DA; Landry JW
Mol Cancer Res; 2021 Aug; 19(8):1338-1349. PubMed ID: 33811160
[TBL] [Abstract][Full Text] [Related]
4. BPTF promotes hepatocellular carcinoma growth by modulating hTERT signaling and cancer stem cell traits.
Zhao X; Zheng F; Li Y; Hao J; Tang Z; Tian C; Yang Q; Zhu T; Diao C; Zhang C; Chen M; Hu S; Guo P; Zhang L; Liao Y; Yu W; Chen M; Zou L; Guo W; Deng W
Redox Biol; 2019 Jan; 20():427-441. PubMed ID: 30419422
[TBL] [Abstract][Full Text] [Related]
5. Bromodomain inhibition targeting BPTF in the treatment of melanoma and other solid tumors.
Khan I; Kashani-Sabet M
Clin Exp Metastasis; 2024 Apr; ():. PubMed ID: 38683257
[TBL] [Abstract][Full Text] [Related]
6. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer.
Song H; Wu T; Xie D; Li D; Hua K; Hu J; Fang L
Cell Physiol Biochem; 2018; 48(5):1968-1982. PubMed ID: 30092563
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of bromodomain PHD finger transcription factor in ovarian cancer and its critical role for cancer cell proliferation and survival.
Miao J; Zhang M; Huang X; Xu L; Tang R; Wang H; Han S
Biochem Cell Biol; 2021 Jun; 99(3):304-312. PubMed ID: 32985220
[TBL] [Abstract][Full Text] [Related]
8. Compound C620-0696, a new potent inhibitor targeting BPTF, the chromatin-remodeling factor in non-small-cell lung cancer.
Xu J; Wang Q; Leung ELH; Li Y; Fan X; Wu Q; Yao X; Liu L
Front Med; 2020 Feb; 14(1):60-67. PubMed ID: 31104301
[TBL] [Abstract][Full Text] [Related]
9. BPTF in bone marrow provides a potential progression biomarker regulated by TFAP4 through the PI3K/AKT pathway in neuroblastoma.
Jiang C; Yang Y; He S; Yue Z; Xing T; Chu P; Yang W; Chen H; Zhao X; Yu Y; Zhang X; Su Y; Guo Y; Ma X
Biol Proced Online; 2023 May; 25(1):11. PubMed ID: 37170211
[TBL] [Abstract][Full Text] [Related]
10. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
[TBL] [Abstract][Full Text] [Related]
11. BPTF transduces MITF-driven prosurvival signals in melanoma cells.
Dar AA; Majid S; Bezrookove V; Phan B; Ursu S; Nosrati M; De Semir D; Sagebiel RW; Miller JR; Debs R; Cleaver JE; Kashani-Sabet M
Proc Natl Acad Sci U S A; 2016 May; 113(22):6254-8. PubMed ID: 27185926
[TBL] [Abstract][Full Text] [Related]
12. The Role and Mechanism of CRT0066101 as an Effective Drug for Treatment of Triple-Negative Breast Cancer.
Liu Y; Wang Y; Yu S; Zhou Y; Ma X; Su Q; An L; Wang F; Shi A; Zhang J; Chen L
Cell Physiol Biochem; 2019; 52(3):382-396. PubMed ID: 30845378
[TBL] [Abstract][Full Text] [Related]
13. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-3666 inhibits lung cancer cell proliferation, migration, and invasiveness by targeting BPTF.
Pan L; Tang Z; Pan L; Tang R
Biochem Cell Biol; 2019 Aug; 97(4):415-422. PubMed ID: 30481052
[TBL] [Abstract][Full Text] [Related]
15. BPTF activates the MAPK pathway through coexpression with Raf1 to promote proliferation of T-cell lymphoma.
Bai D; Zhou Y; Shen F; Gao D; Suo W; Zhang H; Li H
Oncol Lett; 2022 Jul; 24(1):223. PubMed ID: 35720479
[TBL] [Abstract][Full Text] [Related]
16. BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancer.
De Santis F; Romero-Cordoba SL; Castagnoli L; Volpari T; Faraci S; Fucà G; Tagliabue E; De Braud F; Pupa SM; Di Nicola M
Cell Oncol (Dordr); 2022 Apr; 45(2):257-274. PubMed ID: 35357654
[TBL] [Abstract][Full Text] [Related]
17. ESM1 promotes triple-negative breast cancer cell proliferation through activating AKT/NF-κB/Cyclin D1 pathway.
Liu W; Yang Y; He B; Ma F; Sun F; Guo M; Zhang M; Dong Z
Ann Transl Med; 2021 Apr; 9(7):533. PubMed ID: 33987231
[TBL] [Abstract][Full Text] [Related]
18. Long noncoding RNA Linc00339 promotes triple-negative breast cancer progression through miR-377-3p/HOXC6 signaling pathway.
Wang X; Chen T; Zhang Y; Zhang N; Li C; Li Y; Liu Y; Zhang H; Zhao W; Chen B; Wang L; Yang Q
J Cell Physiol; 2019 Aug; 234(8):13303-13317. PubMed ID: 30618083
[TBL] [Abstract][Full Text] [Related]
19. Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells.
Bilir B; Kucuk O; Moreno CS
J Transl Med; 2013 Nov; 11():280. PubMed ID: 24188694
[TBL] [Abstract][Full Text] [Related]
20. Long Non-coding RNA BTG3-7:1 and JUND Co-regulate
Dan Z; Xiujing H; Ting L; Xiaorong Z; Hong Z; Jiqiao Y; Yanchu L; Jing J
Front Mol Biosci; 2020; 7():605623. PubMed ID: 33585557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
